Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study.

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: onr:"swepub:oai:DiVA.org:uu-431895" > Different patterns ...

1 of 1
Previous record
Next record
To hitlist

Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic) : A multinational observational study.

Persson, Frederik (author)

Bodegard, Johan (author)

Lahtela, Jorma T (author)

Nyström, Thomas (author): Karolinska Institutet

Jørgensen, Marit E (author)

Jensen, Majken Linneman (author)

Gulseth, Hanne L (author)

Thuresson, Marcus (author)

Hoti, Fabian (author)

Nathanson, David (author): Karolinska Institutet

Norhammar, Anna (author): Karolinska Institutet

Birkeland, Kåre I (author)

Eriksson, Johan G (author)

Eriksson, Jan (author): Uppsala universitet,Klinisk diabetologi och metabolism

show less...

(creator_code:org_t)

2018-08-31
2018
English.
In: Endocrinology, diabetes & metabolism. - : Wiley. - 2398-9238. ; 1:4

Related links:: https://doi.org/10.1...; show more...; https://onlinelibrar...; https://urn.kb.se/re...; https://doi.org/10.1...; http://kipublication...; show less...

Journal article (peer-reviewed)

Abstract Subject headings

Aims: The understanding of second-line use of glucose-lowering drugs (GLDs) in the general population with type 2 diabetes (T2D) treatment is important as recent results have shown cardiovascular benefits with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA). Our aim was to describe second-line GLD treatment patterns in four Nordic countries.Methods: All T2D patients treated with GLD between 2006 and 2015 were identified in prescribed drug registries in Denmark, Finland, Norway and Sweden, and linked with National Patient and Cause of Death Registries. Second-line treatment was defined as a prescription of a second GLD class following ≥6 months of metformin monotherapy. Index was the date of first dispense of the second-line drug.Results: A rapid uptake of newer GLDs (GLP-1RA, DPP-4i and SGLT-2i) over the 10-year observation period was seen in Denmark, Finland and Norway, while slower in Sweden. In 2015, 33,880 (3.1%) of 1,078,692 T2D patients initiated second-line treatment, and newer GLDs were more commonly used in Finland (92%), Norway (71%) and Denmark (70%) vs Sweden (44%). In 2015, the use of older GLDs (insulin and sulphonylureas) was 7-fold greater in Sweden compared to Finland (49% vs 7%), and 1.6-fold greater compared with Denmark and Norway (49% vs 30% and 29%, respectively).Conclusions: Despite comparable demography and healthcare systems in four neighbouring countries, surprisingly large differences in second-line use of newer GLDs were found. With recent evidence of potential cardiovascular benefits with newer GLDs, such differences may have an important impact on cardiovascular outcomes.

Keyword

SGLT2
observational study
second‐line
type 2 diabetes

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

Endocrinology, diabetes & metabolism (Search for host publication in LIBRIS)

To the university's database

1 of 1
Previous record
Next record
To hitlist

Find more in SwePub

By the author/editor: Persson, Frederi ...; Bodegard, Johan; Lahtela, Jorma T; Nyström, Thomas; Jørgensen, Marit ...; Jensen, Majken L ...; show more...; Gulseth, Hanne L; Thuresson, Marcu ...; Hoti, Fabian; Nathanson, David; Norhammar, Anna; Birkeland, Kåre ...; Eriksson, Johan ...; Eriksson, Jan; show less...

Articles in the publication: Endocrinology, d ...

By the university: Uppsala University; Karolinska Institutet

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se